Zydus Lifesciences Receives VAI Classification from FDA

  Published 9 months ago

Zydus Lifesciences received a VAI classification from the USFDA after an April 2025 inspection at its Dabhasa API facility, now closed.

  • Inspection conducted April 21-25, 2025, at Dabhasa facility near Vadodara for API manufacturing.
  • VAI classification requires voluntary corrective actions, not formal FDA enforcement actions.
  • Inspection closed by FDA with no immediate regulatory actions or warnings indicated.

You might like these

Ola Electric Launches MoveOS 5 for Enhanced EV Performance

India Approves E20 Fuel Nationwide

EV Sales Surge in India: 7.7% Market Share

Reliance-Google Cloud AI Alliance

Nomura: India's Counter to US Tariffs

Bharat Dynamics Dips on Valuation Call

Japan's Exports Dip Amidst US Tariffs

News that matters the most ⚡